De-risk your CRISPR pipeline with scalable cGMP guide RNA

Tuesday, April 8, 2025 – 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT

Join us for an exclusive webinar with Dr. Pedro Teh as he explores how expert guide RNA (gRNA) manufacturing services can help accelerate your CRISPR-based therapeutic development in line with current good manufacturing practices (cGMP).

As a trusted partner in cell and gene therapy, GenScript provides high-quality, scalable, and regulatory-compliant gRNA for CRISPR systems including Cas9, Cas12a, prime editing, and base editing.

Discover how GenScript's cGMP synthesis capabilities and state-of-the-art production facility ensures a streamlined 30-day turnaround for clinical-grade gRNA, and see how comprehensive documentation support – including Drug Master Files (DMFs) – can facilitate smooth investigational new drug (IND) submissions and regulatory approvals.

Whether you're in early-stage research or preparing for clinical trials, this webinar will show you how GenScript's expertise in cGMP nucleic acid manufacturing, quality control, and regulatory support can help de-risk and accelerate your CRISPR therapeutic pipeline.

Key learning objectives:

• Learn about cGMP guide RNA manufacturing and quality control processes
• Explore a range of gene editing approaches that can be supported by cGMP gRNA services
• Understand how expert documentation support simplifies IND submissions and regulatory approvals
• Learn why procuring RUO to cGMP gRNA from a single vendor streamlines and de-risks the development process for CRISPR therapies

Who should attend?

Scientists and decision-makers from biopharma, biotech, and academic institutions using gene editing for discovery or preclinical research.

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.